Latest Shareholder Approvals News

Sigma Healthcare has successfully passed all key resolutions at its extraordinary general meeting, clearing a major hurdle for its proposed merger with Chemist Warehouse. The deal now awaits final court approval, with implementation expected in February.

ReNu Energy has raised $500,000 through loan notes that may convert into shares and options pending shareholder approval, aiming to bolster working capital.

New Murchison Gold Limited reports a significant 39% increase in indicated gold resources at its Crown Prince deposit and secures a strategic ore purchase deal with Westgold, setting the stage for mining to commence mid-2025.

Minerals 260 Limited has executed a binding agreement to acquire the Bullabulling Gold Project, a major gold resource in Western Australia, setting the stage for a transformative 2025. The acquisition brings a substantial 2.3 million ounce gold resource and signals a strategic pivot towards near-term production.

InVert Graphite Limited has secured shareholder approval for a transformative acquisition of a Tanzanian graphite project and rebranded from Dominion Minerals, positioning itself for a strategic relisting on the ASX.

Trek Metals has reported impressive high-grade gold intercepts at its Christmas Creek Project in Western Australia, signaling the potential for a significant orogenic gold system. The company is advancing its exploration with refined drilling targets and ongoing work at its McEwen Hills Niobium Project.

Rox Resources has completed its $27 million capital raising with the final tranche of shares issued to institutional investors and company directors, signaling strong backing for its growth plans.

Iltani Resources reports breakthrough drilling results at its Orient Silver-Indium Project, delivering Australia’s highest-grade silver-indium intercepts to date, alongside promising antimony mineralisation at Antimony Reward.

Arrow Minerals has secured $7 million through a well-supported placement to advance its flagship Niagara Bauxite and Simandou North Iron projects in Guinea, setting the stage for key resource milestones and development studies.

I Synergy Group Limited has successfully completed a $100,000 private placement at a 16.67% discount, aiming to bolster its growth and working capital. The move signals investor confidence as the technology company advances its digital solutions agenda.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.